Back to Authors

Murphy, Michael Desmond

A5109281572 | I145311141

Mayo Clinic

Alnylam Pharmaceuticals (United States)

Citations 2

Comparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025b26anqr1

Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025v7er7rv3